Pancreatic Cancer – Unmet Need – Detailed, Expanded Analysis (US/EU)
Pancreatic adenocarcinoma is an aggressive malignancy associated with an extremely poor prognosis and high lethality. The metastatic setting is the largest drug-treatable population in pancreatic cancer, constituting the highest number of drug-treatment opportunities. Nevertheless, current treatment options are limited to chemotherapy-based regimens, such as FOLFIRINOX or gemcitabine in combination with Abraxane, which offer only modest survival benefits. There is, therefore, significant unmet need for novel therapies that can offer a substantial survival gain. Targeted therapies such as Tarceva (Roche), Lynparza (AstraZeneca; maintenance), and Keytruda (Merck & Co.; MSI-H tumors) are also approved in this indication. In this report, we evaluate the performance of key drugs based on key drug attributes and their impact on physicians’ prescribing behavior. We also explore attributes that will favor the uptake of novel therapies in this space and highlight relevant drug development opportunities.
QUESTIONS ANSWERED
- How important are specific drug attributes in medical oncologists’ prescribing decisions? What are the key influences on treatment decisions and hidden opportunities for drug development?
- How do key current therapies perform on key clinical drug attributes for this patient population?
- What are the greatest unmet needs and most attractive opportunities in this indication?
- What trade-offs are surveyed medical oncologists willing to make across key drug attributes and price for a new therapy?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in November 2023
Key drugs: Gemcitabine, Abraxane, Onyvide, Tarceva, Lynparza, Keytruda
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
KEY FEATURE
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Rajashri Lella, M.Pharm., Associate Healthcare Research & Data Analyst, Oncology. Ms. Lella performs secondary market research, which includes patent research and pricing for major pharmaceutical markets covering multiple oncology indications. She previously worked on Clarivate’s Oncology Clinical Trial Monitor. Ms. Lella completed a master’s degree in pharmaceutical quality assurance at Manipal Academy of Higher Education in India.